Scribe Therapeutics

company

About

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Details

Last Funding Type
Series A
Last Funding Money Raised
$20M
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
Scribe Therapeutics Inc

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.

Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.

Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$120M
Scribe Therapeutics has raised a total of $120M in funding over 2 rounds. Their latest funding was raised on Mar 31, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 31, 2021 Series B $100M 9 Avoro Capital Advisors
Avoro Ventures
Detail
Jan 1, 2018 Series A $20M 1 Andreessen Horowitz Detail

Investors

Number of Lead Investors
Number of Investors
3
9
Scribe Therapeutics is funded by 9 investors. Avoro Capital Advisors and Avoro Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Avoro Capital Advisors Yes Series B
Avoro Ventures Yes Series B
Andreessen Horowitz Series B
Menlo Ventures Series B
OrbiMed Series B
Perceptive Advisors Series B
RA Capital Management Series B
T. Rowe Price Series B
Wellington Management Series B

Employee Profiles

Number of Employee Profiles
10
Scribe Therapeutics has 10 current employee profiles, including Executive Jennifer Doudna
Executive
Board member
Board member
Executive
Executive